A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC

Trial Profile

A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SPLENDOUR
  • Most Recent Events

    • 04 May 2018 This trial has been suspended in Germany.
    • 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top